![]() ![]() ![]() The company has 7 approved antibodies used in 7 marketed products, covering cancer indications and autoimmune diseases. It's a dual listed company with shares traded on the Copenhagen Stock Exchange in Denmark, and on NASDAQ Global Select Market in the US. Jazz Pharmaceuticals employs 2,800 staff and has a trailing 12-month revenue of around 3.7 billion. Jazz Pharmaceuticals shares (JAZZ) are listed on the NASDAQ and all prices are listed in US Dollars. in Utrecht, The Netherlands, Genmab U.S., Inc. Jazz Pharmaceuticals is a biotechnology business based in the US. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. To read this article on click here.Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. 12-month price forecasts for Jazz Pharmaceuticals PLC have a median target of 200. Investors should take the time to consider JAZZ for their portfolios due to its solid Zacks Ranks, notable earnings and valuation metrics, and impressive Value and VGM Style Scores. Yahoo Finance - Stock Market Live, Quotes, Business & Finance News. JAZZ has an average earnings surprise of 12.8%. ![]() The Zacks Consensus Estimate has increased $0.57 to $17.05 per share. 11 analysts revised their earnings estimate upwards in the last 60 days for fiscal 2022. Value investors don't just pay attention to a company's valuation ratios positive earnings play a crucial role, too. Shares of Jazz Pharmaceuticals are trading at a forward earnings multiple of 8.8X, as well as a PEG Ratio of 1.1, a Price/Cash Flow ratio of 6.5X, and a Price/Sales ratio of 2.8X. JAZZ boasts a Value Style Score of A and VGM Score of A, and holds a Zacks Rank #3 (Hold) rating. The company's revenue skyrocketed by more than 1,700 in the latest quarter as it received support from its collaborator Jazz Pharmaceuticals PLC ( JAZZ) to develop and commercialize. Xywav was also approved for treating idiopathic hypersomnia (IH). See the company profile for Jazz Pharmaceuticals plc (JAZZ) including business summary, industry/sector information, number of employees, business summary. Both drugs are approved for treating cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients. Lets consider two stocks that could help investors profit from this opportunity: Jazz Pharmaceuticals (NASDAQ: JAZZ) and Innovative Industrial Properties (NYSE. ![]() Xywav is a low-sodium formulation of Jazz’s legacy drug, Xyrem, which was launched in 2020. The company derives the majority of its revenues from its sleep disorder drugs - Xywav and Xyrem. Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote & history Yahoo Finance JAZZ - Jazz Pharmaceuticals plc NasdaqGS - NasdaqGS Real-time price. Common Stock (SXTP) stock quote, history, news and other vital information to help you with your stock trading and investing. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks.ĭublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience and oncology. Find the latest 60 Degrees Pharmaceuticals, Inc. Different than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on. Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote & history Yahoo Finance JAZZ - Jazz Pharmaceuticals plc NasdaqGS - NasdaqGS Real-time price. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |